FLT3 and acute myeloid leukemia: An anti-FMS-related tyrosine kinase 3 (FLT-3) mAb with Ser239Asp and Ile332Glu mutations is part of a clinical phase I/II trial to treat patients with acute myeloid leukemia (AML) (ClinicalTrials.gov identifier: NCT02789254).